Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Besser

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Research and Practice in Thrombosis and Haemostasis|February 2, 2022
Direct oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitorsDanielle White, Gary W Moore, Martin Besser, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 27, 2022
Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)Daniel Aston, Martin Besser, Ben Goddard, et al.
Scientific Reports|February 1, 2024
The value-based price of transformative gene therapy for sickle cell disease: a modeling analysisGeorge Morgan, Emily Back, Martin Besser, et al.
Journal of Cardiothoracic and Vascular Anesthesia|July 5, 2020
Evaluation of Point-of-Care ACT Coagulometers and Anti-Xa Activity During Cardiopulmonary BypassFlorian Falter, Stephen MacDonald, Claire Matthews, et al.
The Lancet. Child & Adolescent Health|April 16, 2021
Juvenile haemochromatosisWilliam J H Griffiths, Martin Besser, David J Bowden, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|April 1, 2020
Pulsatile Versus Nonpulsatile Flow During Cardiopulmonary Bypass: Extent of Hemolysis and Clinical SignificanceZihui Tan, Martin Besser, Simon Anderson, et al.
British Journal of Haematology|October 2, 2014
Is the continued use of UK plasma sourced cryoprecipitate justified? Response to MakrisSaad F Idris, Andreas V Hadjinicolaou, Mark Sweeney, et al.
British Journal of Haematology|April 15, 2014
The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemiaSaad F Idris, Andreas V Hadjinicolaou, Mark Sweeney, et al.
British Journal of Haematology|November 17, 2018
Utility of the DASH score after unprovoked venous thromboembolism; a single centre studyStephen MacDonald, Rajani Chengal, Anida Hanxhiu, et al.
Journal of Patient-Reported Outcomes|September 26, 2024
Economic burden and quality of life of caregivers of patients with sickle cell disease in the United Kingdom and France: a cross-sectional studyMartin Besser, Sian Bissell O'Sullivan, Siobhan Bourke, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Research and Practice in Thrombosis and Haemostasis|February 2, 2022
Direct oral anticoagulants-Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitorsDanielle White, Gary W Moore, Martin Besser, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 27, 2022
Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)Daniel Aston, Martin Besser, Ben Goddard, et al.
Scientific Reports|February 1, 2024
The value-based price of transformative gene therapy for sickle cell disease: a modeling analysisGeorge Morgan, Emily Back, Martin Besser, et al.
Journal of Cardiothoracic and Vascular Anesthesia|July 5, 2020
Evaluation of Point-of-Care ACT Coagulometers and Anti-Xa Activity During Cardiopulmonary BypassFlorian Falter, Stephen MacDonald, Claire Matthews, et al.
The Lancet. Child & Adolescent Health|April 16, 2021
Juvenile haemochromatosisWilliam J H Griffiths, Martin Besser, David J Bowden, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|April 1, 2020
Pulsatile Versus Nonpulsatile Flow During Cardiopulmonary Bypass: Extent of Hemolysis and Clinical SignificanceZihui Tan, Martin Besser, Simon Anderson, et al.
British Journal of Haematology|October 2, 2014
Is the continued use of UK plasma sourced cryoprecipitate justified? Response to MakrisSaad F Idris, Andreas V Hadjinicolaou, Mark Sweeney, et al.
British Journal of Haematology|April 15, 2014
The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemiaSaad F Idris, Andreas V Hadjinicolaou, Mark Sweeney, et al.
British Journal of Haematology|November 17, 2018
Utility of the DASH score after unprovoked venous thromboembolism; a single centre studyStephen MacDonald, Rajani Chengal, Anida Hanxhiu, et al.
Journal of Patient-Reported Outcomes|September 26, 2024
Economic burden and quality of life of caregivers of patients with sickle cell disease in the United Kingdom and France: a cross-sectional studyMartin Besser, Sian Bissell O'Sullivan, Siobhan Bourke, et al.
Pageof 5